Drug intelligence / Profile preview

BR1016A

Development stage: Unknown
Lead developer: Boryung
Modality: Small Molecules
Administration: Oral

Overview

BR1016A is an investigational drug initially developed by Boryung Corp. for the treatment of cardiovascular diseases, with a specific focus on chronic heart failure. The drug has completed a Phase 1 clinical trial to evaluate its pharmacokinetics and safety in healthy volunteers, but its mechanism of action and exact drug type remain undisclosed in available public sources[1][2][3].

Beyond the preview

Go deeper on BR1016A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR1016A.

Explore the full profile